Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of sublingual dexmedetomidine for treatment of agitation

一种右旋美托咪啶、激越的技术，应用在舌下右旋美托咪啶用于治疗激越的用途领域，能够解决激越治疗有限等问题

Pending Publication Date: 2019-10-15
BIOXCEL THERAPEUTICS INC
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For example, benzodiazepines or fast-acting sedatives quickly sedate severely agitated patients, but continued treatment with these agents can lead to tolerance
[0013] Therefore, agitation therapy for patients with neuropsychiatric disorders (such as schizophrenia or bipolar mania) and neurodegenerative disorders remains limited due to possible differences with currently used drugs, their routes of administration (intravenous / muscular significant side effects associated with the need to subsequently require a hospital setting to administer these drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of sublingual dexmedetomidine for treatment of agitation
  • Use of sublingual dexmedetomidine for treatment of agitation
  • Use of sublingual dexmedetomidine for treatment of agitation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach 1

[0168] Embodiment 1. A method for treating agitation or signs of agitation in a subject in need thereof, said method comprising sublingually administering to said subject an effective amount of dexmedetomidine, or a pharmaceutically acceptable amount thereof. Accepted salt.

Embodiment approach 2

[0169] Embodiment 2. A method for treating agitation or signs of agitation in a subject in need thereof, said method comprising administering to said subject an effective amount of dexmedetomidine or a pharmaceutically acceptable salt, wherein the dexmedetomidine or a pharmaceutically acceptable salt thereof is administered sublingually in a dose to treat agitation or signs of agitation without causing significant sedation.

Embodiment approach 3

[0170] Embodiment 3. The method according to embodiment 1 or 2, wherein the dose of dexmedetomidine or a pharmaceutically acceptable salt thereof ranges from about 3 micrograms to about 100 micrograms (eg, from about 5 micrograms to about 100 micrograms, about 5 micrograms to about 90 micrograms, about 5 micrograms to about 85 micrograms, about 5 micrograms to about 80 micrograms, about 5 micrograms to about 75 micrograms, about 5 micrograms to about 70 micrograms, about 5 micrograms to about 65 micrograms , about 5 micrograms to about 60 micrograms, about 5 micrograms to about 55 micrograms, about 5 micrograms to about 50 micrograms, about 5 micrograms to about 45 micrograms, about 5 micrograms to about 40 micrograms, about 5 micrograms to about 35 micrograms, about 5 micrograms to about 30 micrograms, about 5 micrograms to about 25 micrograms, about 5 micrograms to about 20 micrograms, about 5 micrograms to about 15 micrograms, about 5 micrograms to about 10 micrograms, less ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an [alpha]-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and / or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an [alpha]-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.

Description

[0001] invention technology [0002] The present invention discloses a method for treating agitation or signs of agitation in a subject, the method comprising sublingually administering an effective amount of an alpha-2 adrenergic agonist, more particularly dexmedetomidine or its Pharmaceutically acceptable salts. The present invention also discloses a sublingual composition for treating agitation or signs of agitation and its preparation. The sublingual composition comprises an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof and one or Various pharmaceutically acceptable carriers and / or excipients. [0003] Cross References to Related Applications [0004] This application claims U.S. Provisional Application Serial No. 62 / 441,164 filed December 31, 2016, U.S. Provisional Application Serial No. 62 / 471,393 filed March 15, 2017, and U.S. Provisional Application Serial No. 62 / 471,393 filed August 8, 2017 62 / 542,323, the disclosure of which is he...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/415A61K31/4174
CPCA61K45/06A61K31/4174A61K47/10A61K9/006A61K9/2027A61P25/00A61K2300/00A61P25/22
Inventor K.南达巴兰F.约卡S.夏尔马
Owner BIOXCEL THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com